Thierry Alcindor

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

Ian Judson, Jaap Verweij, Hans Gelderblom et al. · The Lancet Oncology · 2014 · 1.1K citations · Full text

Metastatic Soft-tissue Sarcoma, Versus Intensified Doxorubicin, Oncology +7

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

William D. Tap, Hans Gelderblom, Emanuela Palmerini et al. · The Lancet · 2019 · 454 citations · Full text

Surgical Oncology, Oncology, Medicine +9

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

William D. Tap, Zsuzsanna Pápai, Brian A. Van Tine et al. · The Lancet Oncology · 2017 · 293 citations · Full text

Medicine, Randomised Phase 3, Metronomic Therapy +7

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 276 citations · Full text

First-line Therapy, Gastrointestinal Oncology, Medicine +6

Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy

George D. Demetri, Sant P. Chawla, Isabelle Ray‐Coquard et al. · Journal of Clinical Oncology · 2013 · 239 citations